![Web Web](/content/dam/global/hcpportal/master/images/homepage/products/duac/2017/4-3-Graph-a.jpg)
EDF S3-Guideline for the treatment of acne (Updated 2016):
- Highest recommendation for fixed-dose combinations of Benzoyl Peroxide (BPO) + clindamycin (Duac) or BPO + adapalene as first-line therapy for the treatment of mild to moderate papulopustular acne 1
- Recommends against the use of topical antibiotic monotherapies to reduce the development of antibiotic resistance 1
![Web Web](/content/dam/global/hcpportal/master/images/homepage/products/duac/2017/4-3-Graph-b.jpg)
AAD Guidelines of care for the management of acne vulgaris (Updated 2016):
![Web Web](/content/dam/global/hcpportal/master/images/homepage/products/duac/2017/4-3-Graph-c.jpg)
References:
- Nast A et al. JEADV 2016;30(8):1261–1268.
- Zaenglein AL et al. J Am Acad Dermatol 2016;74(5):945–973.e33.
- Data on File: 2016N276844_00; Glycerol and Dimeticone Content of Clindamycin 1% Benzoyl Peroxide 3% Gel, GlaxoSmithKline, March 2016.
- Data on File: 2016N276774_00; Glycerol and Dimeticone Content of Clindamycin 1% Benzoyl Peroxide 5% Gel, GlaxoSmithKline, March 2016.
- Eichenfield LF et al. J Drugs Dermatol 2011;10:1382–1396.
- Schaller M et al. J Eur Acad Dermatol Venereol 2016; 30:966–973.
Duac is a registered trademark of Stiefel, a GSK company.